SCHEMBL5895254

SCHEMBL5895254

O=C(O)C(=Cc1ccc(-c2cccc(Cl)c2Cl)o1)NC(=O)c1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 10/20 0.53
▸ MAPK1 P28482 7/20 0.53
▸ KDM4E B2RXH2 5/20 0.53
▸ ALDH1A1 P00352 4/20 0.53
▸ SMN1; SMN2 Q16637 2/20 0.53
▸ NPSR1 Q6W5P4 4/20 0.51
▸ MITF O75030 3/20 0.51
▸ HTT P42858 2/20 0.51
▸ LMNA P02545 6/20 0.48
▸ MEN1 O00255 4/20 0.45
▸ KMT2A Q03164 4/20 0.45
▸ HPGD P15428 2/20 0.45
▸ ALOX12 P18054 1/20 0.45
▸ POLB P06746 1/20 0.43
▸ GAA P10253 2/20 0.43
▸ NPC1 O15118 1/20 0.43
▸ RAB9A P51151 1/20 0.43
▸ RCE1 Q9Y256 1/20 0.43
▸ SIRT2 Q8IXJ6 1/20 0.42
▸ SIRT1 Q96EB6 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5895246 1.00 MAPT (0.53) MAPTMAPK1KDM4EALDH1A1SMN1; SMN2
SCHEMBL5895235 1.00 MAPT (0.53) MAPTMAPK1KDM4EALDH1A1SMN1; SMN2
SCHEMBL5896506 0.92 MAPT (0.62) MAPTMAPK1KDM4EALDH1A1SMN1; SMN2
SCHEMBL5896497 0.92 MAPT (0.62) MAPTMAPK1KDM4EALDH1A1SMN1; SMN2
SCHEMBL5896487 0.92 MAPT (0.62) MAPTMAPK1KDM4EALDH1A1SMN1; SMN2
SCHEMBL5896197 0.83 MAPT (0.59) MAPTMAPK1KDM4EALDH1A1SMN1; SMN2
SCHEMBL5896174 0.83 MAPT (0.59) MAPTMAPK1KDM4EALDH1A1SMN1; SMN2
SCHEMBL5896187 0.83 MAPT (0.59) MAPTMAPK1KDM4EALDH1A1SMN1; SMN2
SCHEMBL5894979 0.82 MAPK1 (0.50) MAPTMAPK1KDM4EALDH1A1SMN1; SMN2
SCHEMBL5895328 0.82 MAPK1 (0.50) MAPTMAPK1KDM4EALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7041690-B2 Inhibitors of HCV NS5B polymerase PHARMACIA & UPJOHN COMPANY, LLC (US) 2006-05-09 — — US disclosed
US-20060004063-A1 Inhibitors of HCV NS5B polymerase PHARMACIA & UPJOHN COMPANY, LLC 2006-01-05 — — US disclosed
EP-1532128-A1 INHIBITORS OF HCV NS5B POLYMERASE Pharmacia & Upjohn Company LLC (US) 2005-05-25 — — EP disclosed
US-20040142980-A1 Inhibitors of HCV NS5B polymerase PHARMACIA & UPJOHN COMPANY 2004-07-22 — — US disclosed
WO-2004002977-A1 INHIBITORS OF HCV NS5B POLYMERASE PHARMACIA & UPJOHN COMPANY LLC (US) 2004-01-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040142980-A1 Inhibitors of HCV NS5B polymerase POLRMT, POLR1E, CTDSP1 MAPT 3583/4885MAPK1 1713/4885KDM4E 2739/4885
US-20060004063-A1 Inhibitors of HCV NS5B polymerase POLRMT, EIF5B, POLI MAPT 3589/4885MAPK1 2559/4885KDM4E 2538/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback